Limits...
Inhaled insulin: A "puff" than a "shot" before meals.

Brashier DB, Khadka A, Anantharamu T, Sharma AK, Gupta AK, Sharma S, Dahiya N - J Pharmacol Pharmacother (2015 Jul-Sep)

Bottom Line: The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration.Inhaled insulin has been recently approved by Food and Drug Administration (FDA).It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.

ABSTRACT
Diabetes is a metabolic disorder characterized by relative or absolute deficiency of insulin, resulting in hyperglycemia. The main treatment of diabetes relies on subcutaneous insulin administration by injection or continuous infusion to control glucose levels, besides oral hypoglycemic agents for type 2 diabetes. Novel routes of insulin administration are an area of research in the diabetes field as insulin injection therapy is burdensome and painful for many patients. Inhalational insulin is a potential alternative to subcutaneous insulin in the management of diabetes. The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration. Inhaled insulin has been recently approved by Food and Drug Administration (FDA). It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

No MeSH data available.


Related in: MedlinePlus

Insulin inhaler[20]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4544132&req=5

Figure 1: Insulin inhaler[20]

Mentions: It is ultra-rapid-acting insulin which mimics a linear dose-related pharmacokinetic profile in patients of type 1 and 2 DM.[13] Maximum plasma drug concentration reached between 10 and 15 min (Tmax) which is very early compared to regular insulin or other rapidly acting insulin analogues (20-45 min). This is important as it mimics first-phase insulin release after food seen in non-diabetic individuals. Duration of action is around 2-3 hrs.[131415] 60% of the inhaled drugs gets deposited in the lungs.[14] Inhaled insulin is designed to be used within 20 min of beginning a meal [Figure 1].


Inhaled insulin: A "puff" than a "shot" before meals.

Brashier DB, Khadka A, Anantharamu T, Sharma AK, Gupta AK, Sharma S, Dahiya N - J Pharmacol Pharmacother (2015 Jul-Sep)

Insulin inhaler[20]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4544132&req=5

Figure 1: Insulin inhaler[20]
Mentions: It is ultra-rapid-acting insulin which mimics a linear dose-related pharmacokinetic profile in patients of type 1 and 2 DM.[13] Maximum plasma drug concentration reached between 10 and 15 min (Tmax) which is very early compared to regular insulin or other rapidly acting insulin analogues (20-45 min). This is important as it mimics first-phase insulin release after food seen in non-diabetic individuals. Duration of action is around 2-3 hrs.[131415] 60% of the inhaled drugs gets deposited in the lungs.[14] Inhaled insulin is designed to be used within 20 min of beginning a meal [Figure 1].

Bottom Line: The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration.Inhaled insulin has been recently approved by Food and Drug Administration (FDA).It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.

ABSTRACT
Diabetes is a metabolic disorder characterized by relative or absolute deficiency of insulin, resulting in hyperglycemia. The main treatment of diabetes relies on subcutaneous insulin administration by injection or continuous infusion to control glucose levels, besides oral hypoglycemic agents for type 2 diabetes. Novel routes of insulin administration are an area of research in the diabetes field as insulin injection therapy is burdensome and painful for many patients. Inhalational insulin is a potential alternative to subcutaneous insulin in the management of diabetes. The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration. Inhaled insulin has been recently approved by Food and Drug Administration (FDA). It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

No MeSH data available.


Related in: MedlinePlus